10 likes | 87 Views
Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders.
E N D
Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders HepatologyVolume 55, Issue 3, pages 742-748, 30 JAN 2012 DOI: 10.1002/hep.24724http://onlinelibrary.wiley.com/doi/10.1002/hep.24724/full#fig2